Genprex Inc
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. The company's technologies are designed to administer disease-fighting genes to provide new therapies for patient populations with cancer and diabetes. Its oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing pla… Read more
Genprex Inc (GNPX) - Total Assets
Latest total assets as of September 2025: $3.56 Million USD
Based on the latest financial reports, Genprex Inc (GNPX) holds total assets worth $3.56 Million USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Genprex Inc - Total Assets Trend (2015–2024)
This chart illustrates how Genprex Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Genprex Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Genprex Inc's total assets of $3.56 Million consist of 50.4% current assets and 49.6% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 38.8% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2015–2024)
This chart illustrates how Genprex Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Genprex Inc's current assets represent 50.4% of total assets in 2024, a decrease from 61.0% in 2015.
- Cash Position: Cash and equivalents constituted 38.8% of total assets in 2024, down from 57.1% in 2015.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 38.0% in 2015.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Genprex Inc Competitors by Total Assets
Key competitors of Genprex Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Genprex Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Genprex Inc generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Genprex Inc is currently not profitable relative to its asset base.
Genprex Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.67 | 0.86 | 68.15 |
| Quick Ratio | 0.67 | 0.86 | 61.47 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-836.61K | $ -324.79K | $ 30.26 Million |
Genprex Inc - Advanced Valuation Insights
This section examines the relationship between Genprex Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 6.53 |
| Latest Market Cap to Assets Ratio | 0.33 |
| Asset Growth Rate (YoY) | -61.3% |
| Total Assets | $4.12 Million |
| Market Capitalization | $1.35 Million USD |
Valuation Analysis
Below Book Valuation: The market values Genprex Inc's assets below their book value (0.33 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Genprex Inc's assets decreased by 61.3% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Genprex Inc (2015–2024)
The table below shows the annual total assets of Genprex Inc from 2015 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $4.12 Million | -61.35% |
| 2023-12-31 | $10.67 Million | -57.46% |
| 2022-12-31 | $25.09 Million | -41.48% |
| 2021-12-31 | $42.86 Million | +36.65% |
| 2020-12-31 | $31.37 Million | +787.53% |
| 2019-12-31 | $3.53 Million | -61.87% |
| 2018-12-31 | $9.27 Million | +635.90% |
| 2017-12-31 | $1.26 Million | -34.07% |
| 2016-12-31 | $1.91 Million | +365.88% |
| 2015-12-31 | $410.09K | -- |